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Background: Docetaxel is the first chemotherapy agent approved for treatment of metastatic castration-resistant
prostate cancer (mCRPC). The limited survival benefit associated with the quick emergence of resistance and systemic
toxicity diminished its efficacy. JNK-mediated apoptosis is one of the mechanisms of docetaxel activity whereas
ERK1/2-c-Myc-CXCR4 signaling is implicated in the development of resistance and induction of migration. The aim
of this study was to evaluate the hypothesis that the combination treatment with docetaxel and GLIPR1-ΔTM will
synergistically induce greater cell death and inhibit the emergence of resistance and development of metastatic
potential in prostate cancer (PCa) cells.
Methods: The synergistic effects of the docetaxel and GLIPR1-ΔTM were evaluated with DNA fragmentation, DAPI
staining and MTS using paired t-test and isobologram study. The effects of the drugs on JNK and ERK1/2-c-Myc-CXCR4
signaling were evaluated with Western blot, DNA fragmentation, and MTS assays using the JNK inhibitor SP600125, and
CXCR4 siRNA. The results of docetaxel and GLIPR1-ΔTM combination on migration were examined with scratch assay
using the CXCR4 inhibitor AMD3100 while our hypothesis was examined in vivo using VCaP orthotopic xenograft model.
Results: We found that GLIPR1-ΔΤΜ synergized with docetaxel to induce apoptosis in VCaP and PC-3 PCa cells through
induction of JNK signaling and concomitant inhibition of ERK1/2-c-Myc-CXCR4 signaling. We showed that JNK activation
mediates the apoptotic effects of the drug combination and that CXCR4 knockdown increases its efficacy. We also found
that the addition of GLIPR1-ΔΤΜ to docetaxel decreases the migration of VCaP and PC-3 cells. The combination
treatment with docetaxel and GLIPR1-ΔTM inhibited tumor growth and decreased metastatic potential in VCaP
xenografts more than single agents did.
Conclusions: Our data suggested that addition of GLIPR1-ΔTM treatment in PCa cells increases the efficacy of
docetaxel and may inhibit the emergence of drug resistance; potentially permitting a decrease of docetaxel dose for
patients with mCRPC eliminating its systemic toxicities.
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The survival of patients with metastatic castration-
resistant prostate cancer (mCRPC) remains poor despite
the introduction of novel antiandrogens such as enzaluta-
mide and abiraterone [1, 2]. Taxanes, in particular docetaxel
and cabazitaxel, are the only chemotherapy agents that have
been shown to increase survival in mCRPC patients
[3, 4] and recent evidence suggests that these agents
are particularly effective in patients with high Gleason
score primary disease [5].
Despite the long period of docetaxel use, the exact
mechanism(s) of its function is not well-understood.
Docetaxel is believed to stabilize microtubules by arresting
their de-polymerization, leading to disruption of normal
mitosis, G2/M arrest, and inhibition of cell proliferation
[6]. This agent inhibits Bcl-2 and Bcl-xL activity through
decreased gene expression and posttranslational phos-
phorylation, promoting apoptosis in PCa cells [6–8]. In
melanoma cells, docetaxel induces apoptosis through
activation of the c-Jun NH2-terminal kinase (JNK)
pathway, but it also activates the ERK1/2 (Extracellular
signal-regulated kinase 1/2) signaling which seems to
inhibit its apoptotic effects [9]. In addition, docetaxel
increases reactive oxygen species (ROS) production,
which promotes JNK activation in androgen receptor
(AR)- negative PCa cells [10]. Collectively, these data
suggest that docetaxel promotes cancer cell death
through apoptosis mediated by JNK activation.
Even when mCRPC initially responds to treatment with
docetaxel, the disease eventually becomes resistant, which
can be attributed to numerous molecular mechanisms
according to recent studies in different types of cancer.
Mhaidat et al. demonstrated that in melanoma cells
treated with docetaxel, activation of PKCδ is associated
with proapoptotic responses through JNK activation, as
mentioned above, while activation of PKCε enhances pro-
survival signaling through ERK1/2 activation [11]. These
results indicate that under docetaxel treatment, one
pathway downstream of PKC may lead to apoptosis
and another associated with ERK signaling may lead
to cell survival and resistance to docetaxel. Of note,
multiple recent reports demonstrated opposed effects and
negative crosstalk between JNK and ERK1/2 signaling
[12–15], suggesting that ERK1/2 activation by doce-
taxel may inhibit its JNK-mediated apoptotic effects.
Leonetti et al. found that treatment combining docetaxel
with antisense oligodeoxynucleotides against Bcl-2 and
c-Myc led to lower PC-3 cell survival in vitro, and
had higher antitumor efficacy in PC-3 xenografts, than did
docetaxel alone, suggesting that Bcl-2 and c-Myc upregu-
lation may promote resistance to docetaxel as well [16].
Finally, a recent report showed that docetaxel induces the
activation of ERK, which stabilizes c-Myc protein, and
stimulates CXCR4 (C-X-C chemokine receptor type 4)signaling [17]. The same report showed that CXCR4 can,
in turn, activate ERK1/2; these signaling activities establish
a positive feedback resistance loop in response to doce-
taxel [17]. Overall, these findings support the concept that
activation of ERK1/2-c-Myc-CXCR4 pathway can promote
the development of resistance to docetaxel and potentially
inhibit the JNK apoptotic signaling.
Recently, cabazitaxel was shown to be effective in patients
who progressed under abiraterone and enzalutamide after
failure of docetaxel suggesting that taxanes may still be a
reasonable therapeutic approach for these patients [18].
The combination of docetaxel with a novel agent may be
the most reasonable approach to increase the apoptotic
effects of docetaxel and delay or inhibit the development of
resistance. Such combination therapy also has the potential
to reduce effective doses of docetaxel, thereby decreasing
the incidence of docetaxel side effects such as myelo-
suppression [19]. Numerous studies failed to show
improvement of docetaxel efficacy when it was com-
bined with other targeted agents such as dasatinib and
zibotentan [20, 21].
The gene encoding the human glioma pathogenesis-
related protein 1 (GLIPR1), a p53 target, is downregulated
in PCa due to methylation of its promoter [22, 23]. Li et al.
demonstrated that GLIPR1 upregulation leads to accumula-
tion of ROS and subsequent activation of the JNK pathway
and downregulation of Bcl-2 [24]. GLIPR1 was also found
to be associated with destablizing phosphorylation of β-
catenin and c-Myc, leading to their degradation [25]. Our
group recently showed that GLIPR1-ΔTM is selectively
taken up by PCa cells; activates apoptosis through ROS
accumulation; and downregulates c-Myc [26]. Collectively,
these results indicate that GLIPR1-ΔTM may be a good
candidate for combination therapy with docetaxel, since it
promotes PCa specific cell death through JNK activation,
whereas it downregulates c-Myc signaling which has been
extensively associated with the emergence of resistance to
docetaxel through ERK1/2-c-Myc-CXCR4 signaling.
In the current study, we report that GLIPR1-ΔΤΜ
increases the sensitivity of PCa cells to docetaxel in a syn-
ergistic way through additive induction of JNK-mediated
apoptosis in VCaP and PC-3 cells and concurrent inhib-
ition of ERK1/2-c-Myc-CXCR4-mediated development of
resistance. The addition of GLIPR1-ΔTM to docetaxel was
found to decrease the migration of PCa cells while this
combination additively decreased tumor growth and
metastatic potential in VCaP xenografts.
Results
GLIPR1-ΔΤΜ and docetaxel synergistically decreased
survival of VCaP and PC-3 cells in vitro
To test the hypothesis that GLIPR1-ΔTM sensitizes PCa
cells to docetaxel, we used VCaP cells and PC-3 cells.
Both cell lines were derived from bone metastases of
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while PC-3 cells are androgen receptor-negative metastatic
PCa cells. We also included RWPE-1 cells, which are
epithelial cells derived from the peripheral zone of an
histologically normal adult human prostate and transfected
with a single copy of human papillomavirus 18 [26]. The
three cell lines were treated for 48 h with various concen-
trations of docetaxel (0.5, 1, 2, 5, 10, 20, 50, 75, and 100nM)
and GLIPR1-ΔΤΜ (1, 2, 5, 10, 20, 40, 80,and 160 μg/ml) in
different serum concentrations (0.1 % for PC-3 cells and
0.5 % for VCaP and RWPE-1 cells), and MTS assay was
performed to evaluate the dose response and the IC50 for
each single-agent treatment. At a concentration of 0.5nM,
docetaxel resulted in significantly lower survival of both
PCa cell lines (p = 0.004 for VCaP cells, p = 0.03 for PC-3
cells) than did the control treatment (Fig. 1a). The IC50
was 69.8nM for VCaP cells and 70.5nM for PC-3 cells.Fig. 1 GLIPR1-ΔTM reduced VCaP and PC-3 cells’ survival synergistically wit
RWPE-1 cells treated for 48 h, determined using MTS assay. At 0.5nM, doce
IC50 was 69.8nM for VCaP cells and 70.5nM for PC-3 cells. b. GLIPR1-ΔTM d
determined using MTS assay. At 2.5 μg/ml and 10 μg/ml, GLIPR1-ΔTM sign
160 μg/ml decreased survival of RWPE-1 cells. The IC50 was 34.8 μg/ml for
GLIPR1-ΔTM increased the efficacies of all doses of docetaxel in inhibiting
GLIPR1-ΔTM increased the efficacies of 0.5, 1, and 2nM docetaxel in inhibit
80 μg/ml GLIPR1-ΔTM increased the efficacies of 10, 20, and 50nM docetax
synergistically induced cell death in VCaP cells. f. Isobologram analysis show
in PC-3 cells. The results are presented as the mean ± standard error from aDocetaxel significantly decreased survival of normal
prostate cells (RWPE-1) even at the lowest (0.5nM) concen-
tration (p < 0.0001) (Fig. 1a). At 2.5 μg/ml GLIPR1-ΔΤΜ
resulted in significantly decreased survival of VCaP
cells (p = 0.002), and at 10 μg/ml resulted in significantly
decreased survival of PC-3 cells (p = 0.0005) compared to
control treatment (Fig. 1b). The IC50 was 34.8 μg/ml for
VCaP cells and 154 μg/ml for PC-3 cells. Interestingly,
only 160 μg/ml GLIPR1-ΔTM decreased survival of
normal prostate cells (RWPE-1) (p = 0.002) (Fig. 1b),
which is consistent with our previous results [25] showing
that GLIPR1-ΔTM is selectively taken up by cancerous
cells, promoting their apoptosis, while normal prostate
cells are not sensitive to this agent.
To investigate the potential synergy of docetaxel and
GLIPR1-ΔTM in inducing anti-cancer effects, we treated
VCaP and PC-3 cells with various combinations of theh docetaxel. a. Docetaxel dose–response curves of VCaP, PC-3, and
taxel significantly decreased cell survival in the three cell lines. The
ose–response curves of VCaP, PC-3, and RWPE-1 cells treated for 48 h,
ificantly decreased survival of VCaP and PC-3 cells, respectively. Only
VCaP cells and 154 μg/ml for PC-3 cells. c. The addition of 10 μg/ml
VCaP cells’ survival, based on MTS assay. d. The addition of 10 μg/ml
ing PC-3 cells’ survival as determined by MTS assay, and the addition of
el. e. Isobologram analysis showed that GLIPR1-ΔTM and docetaxel
ed that GLIPR1-ΔTM and docetaxel induced cell death synergistically
t least three independent experiments
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in both cell lines; 0, 10, 20, and 40 μg/ml GLIPR1-ΔTM in
VCaP cells; and 0, 10, 20, 40, and 80 μg/ml GLIPR1-ΔTM
in PC-3 cells. At 10 μg/ml, GLIPR1-ΔTM significantly
increased the efficacy of docetaxel in VCaP cells at all
docetaxel doses (Fig. 1c) and significantly increased the
efficacy of docetaxel at 0.5, 1, and 2nM docetaxel in PC-3
cells (Fig. 1d). At 80 μg/ml, GLIPR1-ΔTM signifi-
cantly increased the efficacy of higher doses of docetaxel
(10, 20, and 50nM) (Fig. 1d).
To evaluate whether the effects of combination treat-
ments on survival were super-additive (synergistic), 50 %
of maximum efficacy was used to determine the fixed
ratio, and multiple combination doses with the same
efficacy were included. Isobologram analysis showed
that the effects were synergistic (Fig. 1e, f ).
GLIPR1-ΔTM increased the apoptotic effect of docetaxel
in VCaP and PC-3 cells
Given the known apoptotic effects of GLIPR1-ΔTM
and docetaxel in PCa cells, we hypothesized that the
decreased survival of PCa cells treated with combina-
tions of these two agents is mainly due to increased
apoptosis. To test this hypothesis, we used DAPI
staining and DNA fragmentation assay to examine
apoptosis in VCaP and PC-3 cells. We included
RWPE-1 cells as a control. VCaP and RWPE-1 cells
were treated with 0.5 % serum-containing medium for
24 h, and PC-3 cells were treated with 0.1 % serum-
containing medium for 24 h. Then, cells were treated
with various concentrations of GLIPR1-ΔTM (0, 10,
20, and 40 μg/ml) for 1 h followed by addition of
various concentrations of docetaxel (0, 0.5, 1, 2, 5,
and 10nM). Forty-eight hours later, DAPI staining was
evaluated. At 10 μg/ml, GLIPR1-ΔTM in combination
with all docetaxel concentrations significantly increased
the percentage of apoptotic VCaP cells (p < 0.001) (Fig. 2a).
In PC-3 cells, 10 μg/ml GLIPR1-ΔTM significantly
increased the apoptotic effects of 0.5nM (p = 0.014) and
10nM (p = 0.033) docetaxel, while 20 μg/ml GLIPR1-ΔTM
significantly increased the apoptosis induced by 1nM
docetaxel (p = 0.016) and 40 μg/ml GLIPR1-ΔΤΜ increased
the apoptotic effect of 2nM docetaxel (p = 0.0095) (Fig. 2b).
In RWPE-1 cells, GLIPR1-ΔTM did not increase the
apoptosis induced by any dose of docetaxel, which is
consistent with the results of the cell survival assay and
our previous data showing that GLIPR1-ΔTM selectively
induces apoptosis in PCa cells but not in normal prostate
cells. In RWPE-1 cells, 1nM docetaxel induced apoptosis
(p = 0.0025) (Fig. 2c).
According to DNA fragmentation assay, 10 μg/ml
GLIPR1-ΔTM in combination with all docetaxel doses
increased apoptosis in VCaP cells (p = 0.0014 for 0.5, 1, and
2nM docetaxel; p = 0.0028 for 5nM docetaxel; p = 0.0012for 10nM docetaxel) (Fig. 2d). In PC-3 cells, 10 μg/ml
GLIPR1-ΔTM enhanced the apoptotic effects of all doses
of docetaxel (p = 0.001 for 0.5nM docetaxel; p < 0.001 for 1,
2, 5, and 10nM docetaxel) (Fig. 2e). GLIPR1-ΔTM did not
increase the apoptotic effects of any docetaxel doses in
RWPE-1 cells, in which 0.5nM docetaxel induced apoptosis
(p = 0.0094) (Fig. 2f). Collectively, these results demon-
strated that GLIPR1-ΔTM enhanced the apoptotic activity
of docetaxel in VCaP and PC-3 PCa cells without substan-
tially affecting normal prostate cells.
Combination treatment with docetaxel and GLIPR1-ΔTM
induced JNK signaling and inhibited the docetaxel-induced
ERK1/2-c-Myc-CXCR4 signaling resistance loop, increasing
apoptosis through maximal JNK activation
We have previously demonstrated that endogenous
GLIPR1 activates JNK signaling [22] and docetaxel was
also found to induce JNK signaling and subsequent
apoptosis in melanoma cells [9]. Initially, we hypothesized
that the greater apoptotic effect of the combination of these
two agents is mediated by JNK activation and inhibition of
ERK1/2-c-Myc-CXCR4 signaling by GLIPR1-ΔTM. To
test this hypothesis, we initially examined the effect of com-
bination treatment on JNK and ERK1/2-c-Myc-CXCR4
signaling. To select the right time-point for this evaluation
during treatment using the lowest effective doses, we
examined survival of VCaP and PC-3 cells treated
with 1, 2, or 5nM docetaxel or 10, 20, or 40 μg/ml
GLIPR1-ΔTM. The time-response curves were different
in VCaP and PC-3 cells. In particular, 1nM docetaxel and
10 μg/ml GLIPR1-ΔTM significantly decreased the
survival of VCaP cells at 24 h (p = 0.03 for docetaxel
and p = 0.001 for GLIPR1-ΔTM) (Fig. 3a) and the sur-
vival of PC-3 cells at 48 h (p < 0.001 for docetaxel
and p = 0.007 for GLIPR1-ΔTM) (Fig. 3b).
We next investigated the effect of the combination of
1nM docetaxel and 10 μg/ml GLIPR1-ΔTM on JNK and
ERK1/2-c-Myc-CXCR4 signaling at 24 h for VCaP cells
and 48 h for PC-3 cells. In order to evaluate the role of
JNK signaling in apoptosis and ERK1/2-c-Myc-CXCR4
loop, we included the JNK inhibitor SP600125 in these
experiments, a known agent which acts through inhibiting
JNK phosphorylation [27]. VCaP and PC-3 cells were
treated with 0.5 % or 0.1 % serum-containing medium, re-
spectively, for 24 h. Then, cells were treated with 10 μg/ml
GLIPR1-ΔTM for 1 h followed by addition of 1nM doce-
taxel with or without 1 μM SP600125 for 24 or 48 h.
Western blot experiments were conducted at least three
times and our results reflect at least three independ-
ent experiments. The quantitative data are presented
as supplementary data (Additional file 1: Figure S1).
Representative blots are presented in the Fig. 4. Combin-
ation treatment increased JNK phosphorylation in VCaP
and PC-3 cells more than docetaxel or GLIPR1-ΔTM did
Fig. 2 GLIPR1-ΔTM increased the apoptotic effect of docetaxel in VCaP and PC-3 cells. a. The addition of 10 μg/ml GLIPR1-ΔΤΜ increased the
apoptotic effects of all docetaxel’s doses in VCaP cells, measured by DAPI staining. b. The addition of 10 μg/ml GLIPR1-ΔΤΜ increased the
apoptotic effects of all docetaxel doses in PC-3 cells, measured by DAPI staining. c. GLIPR1-ΔΤΜ did not increase the apoptotic effect of any
docetaxel dose in RWPE-1 cells, while 1nM docetaxel significantly increased the percentage of apoptotic cells, based on DAPI staining. d. The addition
of 10 μg/ml GLIPR1-ΔΤΜ increased the apoptotic effects of all docetaxel doses in VCaP cells, measured by DNA fragmentation. e. The addition of
10 μg/ml GLIPR1-ΔΤΜ increased the apoptotic effects of all docetaxel doses in PC-3 cells, measured by DNA fragmentation. f. GLIPR1-ΔΤΜ did not
increase the apoptotic effect of any docetaxel dose in RWPE-1 cells, while 0.5nM docetaxel significantly increased the percentage of apoptotic cells,
based on DNA fragmentation. The results are presented as the mean ± standard error from at least three independent experiments
Karanika et al. Molecular Cancer  (2015) 14:122 Page 5 of 13when used as single agents (Fig. 4a, b). Based on our
Western blot data, docetaxel alone increased the ERK1/2
phosphorylation (modestly in VCaP cells), and c-Myc and
CXCR4 protein levels whereas the combination treatment
reduced ERK1/2 phosphorylation and c-Myc and CXCR4
protein levels in both cell lines. In contrast, the
addition of SP600125 to the combination treatment
increased ERK1/2 phosphorylation and protein levels
of c-Myc and CXCR4 (Fig. 4a, b).
To further test our hypothesis that JNK mediates the
apoptotic effects of docetaxel and GLIPR1-ΔΤΜ com-
bination treatment, we treated VCaP and PC-3 cells with
DMSO, docetaxel, GLIPR1-ΔΤΜ or combination treat-
ment with or without JNK inhibitor, SP600125, and per-
formed MTS and DNA fragmentation assays to evaluate
survival and apoptosis, respectively. We found that the
percentage of survived VCaP and PC-3 cells treated withthe combination of docetaxel and GLIPR1-ΔTM was sig-
nificantly increased when SP600125 was added (p < 0.001
for both cell lines) according to MTS assay. Additionally,
in PC-3 cells, we also found that the addition of SP600125
increased the survival when added to docetaxel (p = 0.048)
which is consistent with the JNK-mediated apoptotic
effect of docetaxel. Through DNA fragmentation assay,
we found that the addition of SP600125 decreased the
apoptotic effect of docetaxel (p < 0.001 for VCaP and
PC-3 cells), GLIPR1-ΔTM (p < 0.001 for VCaP cells
and p = 0.002 for PC-3 cells) and combination therapy
(p < 0.001 for VCaP and PC-3 cells). Collectively, these
data suggested that docetaxel and GLIPR1-ΔΤΜ com-
bination treatment synergistically increased apoptosis
by maximal activation of JNK, together with suppres-
sion of ERK1/2 signaling, which further increased JNK
signaling through a derepression mechanism. Finally, the
Fig. 3 Time-dependent curves of docetaxel and GLIPR1-ΔTM efficacies in VCaP and PC-3 cells treated with 1, 2, or 5nM docetaxel or 10, 20, or
40 μg/ml GLIPR1-ΔTM. a,b. 1nM docetaxel and 10 μg/ml GLIPR1-ΔΤΜ significantly decreased survival of VCaP cells at 24 h (p = 0.03 for docetaxel
and p = 0.001 for GLIPR1-ΔTM). c,d. Time-dependent curves of docetaxel and GLIPR1-ΔTM efficacies in PC-3 cells treated with 1, 2, or 5nM
docetaxel or 10, 20, or 40 μg/ml GLIPR1-ΔTM showed that 1nM docetaxel and 10 μg/ml GLIPR1-ΔΤΜ significantly decreased survival of these
cells at 48 h (p < 0.001 for docetaxel and p = 0.007 for GLIPR1-ΔTM). The results are presented as the mean ± standard error from at least three
independent experiments
Karanika et al. Molecular Cancer  (2015) 14:122 Page 6 of 13ERK1/2-c-Myc-CXCR4 docetaxel-induced resistance loop
[17], was downregulated by the drug combination which
led to reduced migration activity.
CXCR4 knockdown potentiated the apoptotic effects of
docetaxel and the combination treatment with docetaxel
and GLIPR1-ΔTM decreased the migration of VCaP and
PC-3 cells
We showed that the addition of GLIPR1-ΔTM decreased
the docetaxel-mediated ERK1/2-c-Myc-CXCR4 induc-
tion in VCaP and PC-3 cells. GLIPR1-ΔΤΜ was ex-
pected to further activate the apoptosis and inhibited the
development of resistance through this pathway. We
evaluated the effects of the CXCR4 downregulation on
docetaxel and GLIPR1-ΔTM treatment in terms of
apoptosis and survival of VCaP and PC-3 cells. Thus, we
treated VCaP and PC-3 cells with CXCR4si7 and
CXCR4si8 siRNAs for 48 h and found that the most
effective siRNA in terms of downregulation of CXCR4 is
the CXCR4si7. Consequently, we treated VCaP and PC-
3 cells with CXCR4si7 for 24 h and then treated them
with GLIPR1-ΔΤΜ and docetaxel for 24 and 48 h as
described above. Western blot experiments were con-
ducted three times and the quantitative data are presented
as supplementary data (Additional file 1: Figure S1). We
evaluated the survival with MTS assay and apoptosis with
DNA fragmentation assay. We found that the treatment
with CXCR4si reduced the survival of cells treated withdocetaxel (p < 0.001), GLIPR1-ΔΤΜ (p < 0.001) and com-
bination (p = 0.041) (Fig. 5b) in VCaP cells. According to
DNA fragmentation assay, we found that knockdown of
CXCR4 increased the apoptotic effect of docetaxel
(p < 0.001), GLIPR1-ΔΤΜ (p < 0.001) and combination
(p = 0.01) in VCaP cells (Fig. 5c). In PC-3 cells, we found
that CXCR4 downregulation reduced the survival of
cells treated with docetaxel (p < 0.001), GLIPR1-ΔΤΜ
(p < 0.001) and combination (p < 0.001) (Fig. 5d). According
to DNA fragmentation assay, we found that CXCR4
knockdown increased the apoptotic effect of docetaxel
(p < 0.001), GLIPR1-ΔΤΜ (p < 0.001) and combination
(p < 0.001) in PC-3 cells (Fig. 5e). These data suggested
that CXCR4 downregulation further potentiated the apop-
totic effect of each single agent and their combination as
well, when was combined with them, confirming that the
inhibition of the ERK1/2-c-Myc-CXCR4 resistance
pathway led to increased apoptosis. In our proposed
combination treatment, GLIPR1-ΔΤΜ worked as the
key molecule which reduced CXCR4 levels through
suppression of ERK1/2-c-Myc, and consequently maximally
increased JNK-induced apoptotic signaling stimulated by
docetaxel through ERK1/2 downregulation and JNK dere-
pression. Given the known role of CXCR4 as an inducer of
migration and metastasis in PCa [28], and based on our re-
sults that GLIPR1-ΔTM inhibited the docetaxel-induced
ERK1/2-c-Myc-CXCR4 signaling, we evaluated the hypoth-
esis that the combination of GLIPR1-ΔΤΜ and docetaxel
Fig. 4 GLIPR1-ΔΤΜ synergized with docetaxel in activating JNK/c-Jun through JNK phosphorylation, whereas addition of GLIPR1-ΔΤΜ to
docetaxel reduced ERK1/2 signaling. a,b. VCaP and PC-3 cells were treated with 1nM docetaxel, 10 μg/ml GLIPR1-ΔTM, or both and then, we
added JNK inhibitor (SP600125) 1 μΜ to single agents or to their combination. Total treatment administration lasted for 24 h (VCaP cells) or
48 h (PC-3 cells), and the effects on JNK and ERK1/2 signaling were evaluated via western blot. JNK phosphorylation was increased synergistically
with the combination of docetaxel and GLIPR1-ΔΤΜ, a pathway that leads to apoptosis; whereas ERK1/2 phosphorylation, which results in drug
resistance and migration through c-Myc-CXCR4, was reduced by administration of this combination. These activities were reversed by the JNK
inhibitor, SP600125. Western blot experiments were conducted three times and the quantitative data are presented as supplementary data. c,d.
Under the same conditions and treatments in both cell lines, we performed MTS and DNA fragmentation assay to evaluate the percentage of
survived cells and cell apoptosis, respectively. We found that, in both cell lines, the combination treatment of docetaxel and GLIPR1-ΔΤΜ resulted
in statistically significant decrease in the percentage of survived cells and increase of apoptotic cells (VCaP: p < 0.001 compared to both single
agents in MTS assay, p = 0.02 compared to GLIPR1-ΔΤΜ and p < 0.001 compared to docetaxel according to DNA fragmentation assay, PC-3:
p = 0.001 compared to both single agents in MTS assay, p < 0.001 compared to both single agents according to DNA fragmentation assay) but this
observation was reversed significantly when we added the JNK inhibitor (SP600125) to the combination docetaxel and GLIPR1-ΔΤΜ (p < 0.001 for both
cells lines according to both techniques). The results are presented as the mean ± standard error from at least three independent experiments. e.
Signaling effects of the combination treatment of docetaxel and GLIPR1-ΔΤΜ. Docetaxel induces JNK phosphorylation (apoptosis pathway); whereas
it concomitantly induces ERK1/2 phoshorylation (drug resistance and migration pathway). JNK and ERK1/2 pathways can demonstrate reciprocal
inhibition. GLIPR-ΔΤΜ induces JNK signaling but inhibits the ERK1/2-c-Myc-CXCR4 resistance loop. Thus, docetaxel and GLIPR1-ΔΤΜ combination
treatment leads to JNK pathway dominance over the ERK1/2 pathway, and apoptosis dominates over drug resistance and invasion/migration
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docetaxel alone. We treated VCaP and PC-3 cells with
0.5 % or 0.1 % serum-containing medium, respectively,
followed by 1nM docetaxel, with or without the addition of
10 μg/ml GLIPR1-ΔΤΜ hour before the initiation of doce-
taxel treatment. After 24 h cell migration was assessed byscratch assay. As a positive control, we used 25 μg/ml
AMD3100, a CXCR4 inhibitor, as previously described [29].
The addition of GLIPR1-ΔΤΜ to docetaxel signifi-
cantly decreased the number of migrated VCaP cells
(p < 0.001) (Fig. 5f ) and PC-3 cells (p < 0.001) than
docetaxel alone did (Fig. 5g).
Fig. 5 CXCR4si increased the sensitivity of VCaP and PC-3 cells to docetaxel and reduced cell migration trend when combined with docetaxel.
a. Western blot in VCaP and PC-3 cells to evaluate the efficacy of CXCR4si7 and CXCR4si8 siRNAs. The results are presented as the mean ± standard
error from three independent experiments. Quantitative data of western blots on 2 different CXCR4siRNAs for validation and determination of their
effect size are provided in Supplementary Data. b. CXCR4 knockdown decreased the survival of VCaP cells when was combined with GLIPR1-ΔTM
(p < 0.001), docetaxel (p < 0.001) and combination (p = 0.004) than the CXCR4 knockdown alone did according to MTS assay. c. CXCR4 knockdown
increased the apoptosis of VCaP when was combined with GLIPR1-ΔTM (p < 0.001), docetaxel (p < 0.001) and combination (p = 0.041) than the CXCR4
knockdown did according to DNA fragmentation assay. The results are presented as the mean ± standard error from at least three independent
experiments. d. CXCR4 knockdown decreased the survival of PC-3 cells when was combined with GLIPR1-ΔTM (p < 0.001), docetaxel (p < 0.001) and
combination (p = 0.01) than the CXCR4 knockdown alone did according to MTS assay. e. CXCR4 knockdown increased the apoptosis of PC-3 cells
when combined with GLIPR1-ΔTM (p < 0.001), docetaxel (p < 0.001) and combination (p < 0.001) than the CXCR4 knockdone alone did. The results are
presented as the mean ± standard error from at least three independent experiments. f. Migration of VCaP cells was evaluated by scratch assay after
24 h of treatment with 1nM docetaxel with or without the addition of 10 μg/ml GLIPR1-ΔΤΜ or 25 μg/ml AMD3100, a known CXCR4 inhibitor. The
addition of GLIPR1-ΔTM significantly decreased the number of migrated cells (p < 0.001). g. Migration of PC-3 cells was evaluated by scratch assay after
24 h of treatment with 1nM docetaxel with or without the addition of 10 μg/ml GLIPR1-ΔΤΜ or 25 μg/ml AMD3100. The addition of GLIPR1-ΔTM
significantly decreased the number of migrated cells (p < 0.001). The migration assay experiments were conducted twice and the presented results
are the averages of these two independent experiments
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inhibited growth and metastasis of VCaP othotopic
xenografts
To validate the efficacy of the combination of GLIPR1-
ΔTM and docetaxel in vivo, we treated nude mice bearing
VCaP orthotopic tumors with PBS (control), docetaxel
alone, GLIPR1-ΔTM alone, or the combination of these
two agents. Three weeks after the initiation of treat-
ment, combination treatment significantly decreased theIVIS signal (photons/second) than GLIPR1-ΔTM alone
did (p = 0.012) but docetaxel alone did not (p = 0.16)
(Fig. 6a). However, the tumors that were treated with com-
bination therapy had significantly lower wet weight than
the tumors in the mice treated with docetaxel alone (p =
0.028) or GLIPR1-ΔTM alone (p = 0.0025) did (Fig. 6b).
We collected lymph node samples from all mice and
evaluated them for the presence of metastatic PCa cells as
evidenced by cytokeratin 18 staining. Neither of the two
Fig. 6 Docetaxel GLIPR1-ΔΤΜ combination treatment inhibited growth and metastasis in VCaP orthotopic xenografts. a. Nude mice bearing
VCaP xenografts were treated with docetaxel, GLIPR1-ΔΤΜ, or both. Combination treatment significantly decreased the IVIS signal (photons/s)
than GLIPR1-ΔΤΜ alone did (p = 0.012) but docetaxel alone did not (p = 0.16). b. Combination treatment decreased significantly the wet weight
of VCaP xenografts rather thad GLIPR1-ΔΤΜ alone (p = 0.0025) and docetaxel alone (p = 0.028) did. c. Mouse lymph node tissues were stained for
cytokeratin 18 to evaluate the presence of metastatic VCaP cells. The combination of docetaxel and GLIPR1-ΔΤΜ resulted in a lower incidence of
LN metastasis than control treatment did (p = 0.04), whereas single-agent treatments did not result in a significant reduction
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but combination therapy decreased the incidence of me-
tastasis than control treatment did (p = 0.04) (Fig. 6c).
Discussion
In the present study we tested our hypothesis that
GLIPR1-ΔΤΜ can synergize with docetaxel (one of the
two chemotherapy agents approved for the treatment of
mCRPC) and whether the combination treatment can
lead to greater cell death than treatment with docetaxel
alone does. We showed that the combination of these two
agents had synergistic effects on decreasing cell survival of
VCaP and PC-3 cells. Apoptosis was the main mechanism
for cell death, as demonstrated with DAPI staining and
DNA fragmentation assay. Of note, the combination
treatment appeared to lead to additive induction of JNK
signaling since GLIPR1-ΔΤΜ was found to inhibit theERK1/2-c-Myc-CXCR4 resistance loop and consequently
to suppress the inhibitory effects of ERK1/2 on JNK
signaling, driving JNK signaling. Thus, the efficacy of the
combination of these two agents is suggested to be
mediated through synergistic apoptotic activity driven by
dominant JNK signaling and downregulation of ERK1/
2-c-Myc-CXCR4-mediated drug resistance and migration.
We further tested our hypothesis regarding the JNK
hyperactivation via JNK inhibitor administration using
two biological assays to assess the effect on survival and
apoptosis and western blot to monitor the signaling
changes. We found that the addition of the inhibitor to
the combination treatment resulted in increased survival
and reduced apoptosis compared to combination treat-
ment alone in both PCa cell lines; whereas on Western
blots we observed a marked reduction in JNK phosphor-
ylation together with a concomitant increase in ERK1/2
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compared to combination treatment without inhibitor.
We further tested the effect of CXCR4 downregulation
on combination treatment to determine its role as a
central component of the ERK1/2-c-Myc-stimulated
resistance loop. In support of our hypothesis, we found
that CXCR4 knockdown combined with the combination
treatment further enhanced apoptosis and reduced the
survival of the cells. This finding demonstrates the
opposing biological effects of GLIPR1-ΔΤΜ on c-Myc-
CXCR4-mediated drug resistance and migration [17, 28].
In consideration of this mechanism we tested our hypoth-
esis via migration assay and found that docetaxel and
GLIPR1-ΔΤΜ combination treatment resulted in signifi-
cantly reduced numbers of migrated cells than docetaxel
alone did, mimicking the result of docetaxel combined
with CXCR4 inhibitor and supporting our hypothesis for a
role for GLIPR1-ΔΤΜ suppression of PCa cell migration.
To test our treatment combination effectiveness in vivo,
we treated nude mice bearing VCaP orthotopic xenografts
with docetaxel, GLIPR1-ΔΤΜ, or both for 3 weeks.
Combination treatment decreased IVIS signal than
GLIPR1-ΔΤΜ did and decreased significantly tumor
weight than both single-agent treatments did. The
finding that the incidence of lymph node metastasis
was significantly lower in animals treated with the
combination treatment than in control-treated animals
is consistent with our in vitro data and may be re-
lated to the inhibition of the docetaxel-induced
ERK1/2-CXCR4-c-Myc axis by GLIPR1-ΔTM.
Conclusions
The results of our study demonstrated that docetaxel and
GLIPR1-ΔΤΜ combination treatment leads to increased
JNK-mediated apoptosis compared to single agent treat-
ment. These activities are accompanied by inhibition of
ERK1/2-c-Myc-CXCR4 signaling, which results in de-
repression of JNK signaling, leading to maximal
JNK-mediated apoptotic effects. In addition docetaxel
and GLIPR1-ΔΤΜ combination treatment may suppress
migration through downregulation of the ERK1/2-c-Myc-
CXCR4 drug resistance pathway and reduces metastatic
potential in vivo. Based on our results, its conceivable that
GLIPR1-ΔΤΜ (which is currently progressing toward
clinical trials) or therapy agents that act through similar
mechanisms may be used together with reduced dosage of
docetaxel with potentially greater therapeutic efficacy than
docetaxel alone, and with probably fewer adverse effects.
It is also conceivable that docetaxel and GLIPR1-ΔΤΜ
combination treatment could possibly result in delay in
developing docetaxel resistance. Further preclinical and
clinical studies will be needed to develop GLIPR1-ΔΤΜ
therapy through clinical trials and to evaluate the safety
and efficacy of this combination in patients with mCRPC.Methods
Cell lines and reagents
The non-tumorigenic RWPE-1 cells (from the American
Type Culture Collection) were grown in complete
keratinocyte serum-free medium. PC-3 and VCaP prostate
cancer cells were grown as described previously [26]. All
cell lines were validated by short tandem repeat DNA
fingerprinting with the AmpFlSTR Identifier Kit (Applied
Biosystems, Inc., Foster City, CA) at the Characterized
Cell Line Core Facility of The University of Texas MD
Anderson Cancer Center. Docetaxel and AMD3100, a
CXCR4 inhibitor, were purchased from Sigma-Aldrich
(St. Louis, MO). SP600125, a JNK inhibitor, was purchased
from Santa Cruz.
Purification of recombinant GLIPR1-ΔΤΜ
GLIPR1-ΔTM coding sequence was obtained from
normal prostate tissue by RT-PCR using specific
primers (forward: 5′CCCAAGCTTGCAAATATTTTG
CCAGAT3′, reverse: 5ATAGT TTAGCGGCCGCTCT
GTTACGTGGATATAT3′). The PCR product was digested
with restriction enzymes Hinlll and NotI and inserted
into pSectag/ Hygro2 Hinlll and NotI sites to generate
pSec-GLIPR1-ΔTM as previously described [24, 26].
Conditioned medium from 293 Freestyle cells transfected
with pSec-GLIPR1-ΔTM was collected and centrifuged,
and GLIPR1-ΔTM was purified using Ni-NTA agarose.
Cell viability assay
Cell viability was analyzed using an MTS CellTiter 96
Aqueous One Solution Cell Proliferation Assay (Promega,
Madison, WI) according to the manufacturer’s instructions
as previously described [30]. After appropriate cell treat-
ment (96-well assay plate) 20 μl of CellTiter 96® Aqueous
One Solution Reagent were added into each well. The plate
was intubated for 2 h at 37 °C in a humidified 5 % CO2
chamber. The absorbance at 490 nm was recorded using
the 96-well plate reader.
Apoptosis analysis
Apoptotic nuclear morphology was evaluated with fluor-
escence microscopy after 4′,6-diamidino-2-phenylindole
(DAPI) staining (2 μg/ml). DNA fragmentation analysis
was performed using Cell Death Detection ELISA
(Roche Applied Science, Indianapolis, IN) according to
the manufacturer’s instructions. After the appropriate
treatment, a cell suspension of 2 × 105 cells was collected,
the cells were pelleted by centrifugation and the super-
natant was discarded. 1 mL of PBS was added and the full
volume of re-suspended cells was transferred to 4 mL of
absolute ethanol at −20 °C by pipetting the cell suspension
slowly into the ethanol while vortexing at top speed. The
cells were intubated in ethanol at −20 °C for 5–15°min.
The ethanol was discarded and 5 mL of PBS at room
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solution was diluted to 3 μM in staining buffer
(100 mM Tris, pH 7.4, 150 mM NaCl, 1 mM CaCl2,
0.5 mM MgCl2, 0.1 % Nonidet P-40). After adding
the solution the cell suspension was centrifuged and
the supernatant was discarded. 1 mL of DAPI diluted in
staining buffer was added and the cells were intubated for
15 min at room temperature. The cells’ staining was
analyzed by flow cytometry.DNA fragmentation assay
DNA fragmentation assay was performed using a Cell
Death Detection ELISA Kit (Roche, Mannheim, Germany)
according to manufacturer’s protocol as previously
described [26]. The assay is a photometric enzyme-
immunoassay for the qualitative and quantitative in vitro
determination of cytoplasmic histone-associated DNA
fragments (mono- and oligonucleosomes) after induced
cell death.Isobologram analysis
The effects of drug combinations were categorized as
additive, synergistic, or antagonistic by isobologram
analysis as previously described [31], and IC50 was
used to determine the fixed ratio. A graph of equally
effective dose pairs (isoboles) for a single effect level
is presented. Specifically, a particular effect level of
50 % of the maximum is selected, and doses of docetaxel
and GLIPR1-ΔTM (each alone) that give this effect are
plotted as axial points in a Cartesian plot. The straight
line connecting axial and vertical axes is the locus of
points (dose pairs) that will produce this effect in a
simply additive combination. This line of additivity
allows a comparison with the actual dose pair that
produces this effect level experimentally. An actual
dose pair below the straight line attains this effect
with lesser quantities and is super-additive (synergistic),
while the dose pair denoted above the straight line
means greater quantities are required and is therefore
sub-additive.RNA interference
Knockdown of CXCR4 was achieved by transient trans-
fection of VCaP cells with a pool of CXCR4-specific
siRNA (Invitrogen), and a pool of non-targeting siRNA
(NCsi) (Invitrogen), as control, by using Lipofectamine
RNAiMax transfection reagent (Invitrogen). VCaP cells
were seeded at a density of 1.0 × 106 in six-well plates.
Cells were transfected with 20nM CXCR4si or NCsi the
following day. 24 h later cells were treated with DMSO
or 1 and 2nM of docetaxel in Dulbecco modified Eagle
medium (DMEM) containing 0.5 % serum.Western blot analysis
For evaluation of JNK and ERK1/2-c-Myc-CXCR4 sig-
naling, PC-3 cells were treated for 24 h with RPMI-1640
medium containing 0.1 % serum and VCaP cells were
treated for 24 h with Dulbecco modified Eagle medium
(DMEM) containing 0.5 % serum. Then, cells were
treated with 10 μg/ml GLIPR1-ΔΤΜ for 1 h followed by
the addition of 1nM docetaxel with or without 1μΜ
SP600125 and lysates were collected 24 h later (VCaP
cells) and 48 h later (PC-3 cells). Antibodies against
GLIPR1-ΔΤΜ (Myc-tag), phospho-JNK, JNK, phospho-
ERK1/2, ERK1/2, c-Myc, and CXCR4 were all purchased
from Cell Signaling Technology (Danvers, MA), and anti-
body against GAPDH was purchased from Santa Cruz.
When indicated, densitometric analysis was performed
and quantification of integrated density was assessed using
the NIS-Elements-AR software program (version 3.0;
Nikon) followed by GAPDH normalization.
Scratch assay
PC-3 cells (1 × 105) and VCaP cells (2 × 105) were seeded
in six-well plates and incubated overnight to achieve
confluency. Next day, PC-3 cells were treated for 24 h
with RPMI-1640 medium containing 0.1 % serum, and
VCaP cells were treated for 24 h with DMEM containing
0.5 % serum. Then, the cell layer in each well was
scratched using a plastic pipette tip, and cells were
treated with 10 μg/ml GLIPR1-ΔΤΜ for 1 h followed by
the addition of 1nM docetaxel for 24 h. Cells were visu-
alized under a microscope and photographed for the
evaluation of migration.
Tumor induction in mice, treatment protocols, and
immunohistochemical analysis
VCaP cells were transduced with lentivirus stably ex-
pressing luciferase. Aliquots of 2 × 106 VCaP-luciferase
cells in 25 μl of PBS were injected directly into the right
lobe of the dorsolateral prostate in athymic nude male
mice (Taconic Farms, Hudson, NY) to induce orthotopic
tumors. The tumors were allowed to grow for 14 days
before treatment. Mice were treated with 10 mg/kg
docetaxel intraperitonealy weekly, 20 μg of GLIPR1-ΔTM
intraperitonealy three times per week, or both. The
control group was treated with PBS. Tumor size was
monitored by measuring the luminescence signal using the
IVIS 200 imaging system (PerkinElmer, Wellesley, MA).
After 3 weeks of treatment, tumor-bearing mice were sacri-
ficed, and the tumors were collected and weighed. Lymph
nodes were also collected, and antibody to cytokeratin 18
(DAKO, Carpinteria, CA; catalog no. M701029-2) was used
for immunostaining on formalin-fixed paraffin-embedded
lymph node tissues. All tissue sections were processed by
using an avidin–biotin peroxidase complex kit (Vector
Laboratories, Burlingame, CA) as previously described [32].
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The results are presented as the mean ± standard error
from at least three independent experiments. Comparisons
of groups were appropriately analyzed using the Student-t
test and the Mann–Whitney U test. P values less than 0.05
were considered statistically significant and all tests were
two-tailed. Fisher analysis was used to compare the
incidences of lymph node metastasis in animal tissues.
The isobologram study was used for the determination of
synergy as described above.
Additional file
Additional file 1: Figure S1. Quantitative Data of Westerns Blots
(relevant to Fig. 4a, b). A. VCaP cells densitomentry data B. PC-3 cells
densitometry data. Figure S2 Quantitative data of Western Blots on 2
different CXCR4siRNAs for validation and determination of their effect
size (relevant to Fig. 5a). A. CXCR4si7 is statistically significant in inhibiting
CXCR4 protein expression than NCsi is (p < 0.001) and CXCR4si8 is (p = 0.002)
in VCaP cells. B. CXCR4si7 is statistically significant in inhibiting CXCR4 protein
expression than NCsi is (p < 0.001) and CXCR4si8 is (p = 0.01) in PC-3 cells.
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